Article
Circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers combined with clinicopathological risk has potential to better predict recurrence in stage III breast cancer treated with neoadjuvant chemotherapy: a pilot study.
Breast cancer research and treatment - 1 Oct 2024
Du Kai-Ye, Wu Shang, Ma Xindi, Liu Yunjiang
Abstract excerpt
BACKGROUND: The potential value of detecting epithelial-mesenchymal transition (EMT) CTCs in early breast cancer, especially during the neoadjuvant therapy period, requires further investigation. We analyzed dynamic CTC phenotype status, to improve recurrence risk stratification for patients with stage III breast cancers. METHODS: We enrolled 45 patients with stage III breast cancers from 2 clinical trials...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.